alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>   1
                                                                    EXHIBIT 11.1

                             PAGEMART WIRELESS, INC.
                    COMPUTATION OF PER SHARE EARNINGS (LOSS)

<TABLE>
<CAPTION>
                                                         THREE MONTHS ENDED DECEMBER 31, 1997
                                                        --------------------------------------
                                                         NUMBER        PERCENT      EQUIVALENT
                                                        OF SHARES    OUTSTANDING      SHARES
                                                        ---------    -----------      ------
<S>                                                       <C>             <C>        <C>      
COMMON STOCK
   From Founders' Stock                                  2,300,000       100.00%    2,300,000
   Stock Options Exercised                                 731,072        98.10%      717,194
   Preferred Stock Converted to Common Stock            15,310,943       100.00%   15,310,943
   1994 Common Stock Offerings                          11,242,857       100.00%   11,242,857
   1995 Common Stock Offerings                           4,323,874       100.00%    4,323,874
   1996 Common Stock Offering                            6,000,000       100.00%    6,000,000
   Employee Stock Purchase Plan Shares Issued               75,891        77.24%       58,621
   1997 Warrants Exercised                                  48,300       100.00%       48,300
                                                        ----------                ----------- 
                                                        40,032,937                 40,001,789

WEIGHTED AVERAGE SHARES OUTSTANDING                                                40,001,789

NET LOSS                                                                         ($10,126,000)


NET LOSS PER SHARE                                                                     ($0.25)
                                                                                  ===========
</TABLE>
EXHIBIT 32.2
                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                    AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002


In connection with the quarterly report of Avitar, Inc. (the "Company") on
Form10-QSB/A for the period ending June 30, 2005 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Jay C. Leatherman,
Jr., Chief Financial Officer of the Company certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, to my knowledge, that:


     (1) The Report fully complies with the requirements of Section 13(a)
or15(d) of the Securities Exchange Act of 1934; and

     (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.


Date: February 10, 2006


                                        /s/ Jay C. Leatherman, Jr.
                                        -------------------------
                                        Jay C. Leatherman, Jr.
                                        Chief Financial Officer (Principal
                                        Financial and Accounting Officer),
                                        Secretary
Exhibit 10(A)(3)

Servotronics, Inc. and Subsidiaries


As of May 1, 2002

Dr. Nicholas D. Trbovich
1110 Maple Street
Elma, NY 14059

Dear Dr. Trbovich:

You  and  Servotronics,  Inc.  (the  "Company")  are  parties  to an  employment
agreement, as amended and restated on August 8, 1986 and as subsequently amended
as of October 1, 1986,  October 1, 1987, July 20, 1988, October 1, 1988, October
1, 1989, May 1, 1990, May 1, 1991, May 1, 1992, May 1, 1993, March 28, 1994, May
1, 1994,  May 1, 1995,  May 1, 1996,  May 1, 1997,  March 9, 1998,  May 1, 1998,
October 6, 1998,  April 28, 1999, May 1, 1999, May 1, 2000, May 1, 2001 and July
3, 2001 (the "Agreement"), pursuant to which you are employed by the Company.

This  will  confirm  your  agreement  and  that of the  Company  (pursuant  to a
resolution  of the Board of Directors  passed at a meeting held on July 3, 2002)
to amend Paragraph 3 of the Agreement to delete  "$341,445.00" and insert in its
place "$353,395.00".

Except as specifically provided herein, all of the other terms and conditions of
the Agreement shall remain in full force and effect.

If the  foregoing  meets with your  approval and you are willing to become bound
hereby,  will you please sign and return to the undersigned the enclosed copy of
this letter.

Very truly yours,

SERVOTRONICS, INC.


/S/Lee D. Burns
----------------------------------------
Lee D. Burns
Treasurer/Secretary


ACCEPTED AND AGREED


/S/ Dr. Nicholas D. Trbovich
----------------------------------------
Dr. Nicholas D. Trbovich
§ 876.1800 Urine flow or volume measuring system. ( a ) *Identification.* A urine flow or volume measuring system is a device that measures directly or indirectly the volume or flow of urine from a patient, either during the course of normal urination or while the patient is catheterized. The device may include a drip chamber to reduce the risk of retrograde bacterial contamination of the bladder and a transducer and electrical signal conditioning and display equipment. This generic type of device includes the electrical urinometer, mechanical urinometer, nonelectric urinometer, disposable nonelectric urine flow rate measuring device, and uroflowmeter.
( b ) *Classification.* ( 1 ) Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 876.9.
[48 FR 53023, Nov. 23, 1983, as amended at 61 FR 1122, Jan. 16, 1996; 63 FR 59228, Nov. 3, 1998]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5320 Reservoir bag. ( a ) *Identification.* A reservoir bag is a device, usually made of conductive rubber, intended for use in a breathing circuit as a reservoir for breathing gas and to assist, control, or monitor a patient's ventilation.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 61 FR 1120, Jan. 16, 1996; 66 FR 38794, July 25, 2001]
#### Sharon Cassiani, Plaintiff-Appellant, v. Michael Rogers, Defendant-Appellee.

Gen. No. 68-66.

Third District.

March 26, 1969.

Winstein & Kavensky, of Rock Island, for appellant; Charles Ferguson, of Rock Island, for appellee.

Opinion by

JUSTICE RYAN.

Not to be published in full.
<TABLE> <S> <C>

<ARTICLE> 5
<RESTATED> 
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                           2,629
<SECURITIES>                                     8,677
<RECEIVABLES>                                    7,960
<ALLOWANCES>                                        94
<INVENTORY>                                          0
<CURRENT-ASSETS>                                21,601
<PP&E>                                           2,867
<DEPRECIATION>                                     776
<TOTAL-ASSETS>                                  25,074
<CURRENT-LIABILITIES>                            5,055
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        18,298
<OTHER-SE>                                         903
<TOTAL-LIABILITY-AND-EQUITY>                    25,074
<SALES>                                         27,777
<TOTAL-REVENUES>                                27,777
<CGS>                                                0
<TOTAL-COSTS>                                   15,889
<OTHER-EXPENSES>                                10,736
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 195
<INCOME-PRETAX>                                  1,540
<INCOME-TAX>                                        15
<INCOME-CONTINUING>                              1,525
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     1,525
<EPS-PRIMARY>                                     0.14
<EPS-DILUTED>                                     0.13
        

</TABLE>
UNITED STATES ENVIRONMENTAL PROTECTION AGENCY 

WASHINGTON, D.C. 20460 

MEMORANDUM 

OFFICE Of 

WATER 

SUBJECT: During the Inter-Agency review process for the final rule "federal 

Requirements Under the Underground by'eclion Control (UIC) Program 

for Carbon Dioxide (C02) Geologic Sequestration (GS) Wells " (RlN 

2040-AE98). EPA received the following materials from the Department 

of Energy. They are avail able in the rulemaking docket. 

FROM: Mary Rose Bayer, Geologist fY1~ I?o 

UIC Prevention Branch - OS Rul e Tcam I I Y:;] ><-~p-~--? 

TO: EPA Geologic Sequestration Rulemaking Docket 

Docket No. EPA-HQ-OW-2008-0390 

• Zama Ac id Gas EOR, CO2 Sequestration, and Monitoring Project, by Smith, S.A, 

J. A. Sorensen, E. N. Steadman, J. A. Harju, and D. Ryan. 

• In vestigation Or e02 Plume Behavior ror a Large-Scale Pilot Test of Geologic 

Carbon Storage in a Saline Formation, by Christine Doughty. 

• Plains C02 Reduction (PCOR) Partnership (Phase 11) - lama Field Validation 

Test Regional Technology Implementation Plan (Task 3 - Deliverable 0 52), by 

Smith, S. A., J. A. Sorensen, E. N. Steadman, J. A. Harju, B. Jackson, D. 

Nimchuk, and L. Burke. 

• Impact of Ac id Gas Exposure on Cap Rock Integrity Properties at Apache lama 

EOR & Storage rroject, by Burke, L. 1-1., S. A. Smith, J. A. Sorensen, E. N. 

Steadman, 1. A. Harju, D. Ryan, D. Nimchuk, and B. Jackson. 

Internet Address (URLJ • hl1P twww &pa go~ 

RecyctedlReeyct.ble • Pl1nted with Vegetable Oil Based Inks on 100% Postconsumer, Process Chlol1ne Free Recycled Paper
Exhibit 31.1
**CERTIFICATION REQUIRED BY RULE 13a-14(a) OR RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934**
I, Douglas S. Ramsdale, Chief Executive Officer of Home Products International, Inc., certify that:
          1. I have reviewed this quarterly report on Form 10-Q of Home Products International, Inc.;
          2. Based on my knowledge, this report does not contain any untrue statement of a materialfact or omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report;
          3. Based on my knowledge, the financial statements, and other financial information includedin this report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in this report;
          4. The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and have:
          a) designed such disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that material information relating tothe registrant, including its consolidated subsidiaries, is made known to us by others within thoseentities, particularly during the period in which this report is being prepared;
          b) evaluated the effectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of the disclosure controls andprocedures, as of the end of the period covered by this report based on such evaluation; and
          c) disclosed in this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourthfiscal quarter in the case of an annual report) that has materially affected, or is reasonablylikely to materially affect, the registrant’s internal control over financial reporting; and
          5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and the auditcommittee of the registrant’s board of directors (or persons performing the equivalent functions):
          a) all significant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely to adversely affect theregistrant’s ability to record, process, summarize and report financial information; and
          b) any fraud, whether or not material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting.       Date: May 17, 2005 By: /s/ Douglas S. Ramsdale           Douglas S. Ramsdale    Chief Executive Officer
### Page 1 of 3 **Disposition Comments Docket No:**  

### FAA - 2013 - 0770 These comments are in **Directorate ID:** 

### 2011 - SW - 057 - AD response to an SNPRM Originating Office Tracking No.: **Next Step:** FRAN SNPRM 

### N o C omments/Only

Supportive Comments Received

– If this box is checked, no signatures are required. No 

### Has the reference d service information been revised since the NPRM was issued? I f ye s, lis t latest revision and attach a cop y. Note that changes beyond the scope of the previously published NPRM will require a new notice. Contact the Directorate focal point for guidance. Instructions: Summarize all comments **by issue** (not by commenter) and provide your recommended resolution of each issue. **All comments relating to the sam e issue should be discussed together.**  Do not list all of the issues from one commenter togeth er. If changes to the AD are required based on the comments received, explain why and describe in detail what change(s) you recommend. Reference FAA - IR- M - 8040.1C Chapter 9. **ISSUE 1:** Select one o

f the following : If other, explain : Commenter(s): What change to the AD action is requested? Why is the change requested or how is it justified? Do we agree? If **YES,** we agree because Make the following changes to the AD: If **PARTIALLY AGREE** , we agree with because We disagree with because

Make the following changes to the AD: If **NO** , we don’t agree because **ISSUE 2**  **:** Select one of the following :

If other, explain : Commenter(s): What change to the AD action is requested? Why is the change requested or how is it justified? Do we agree? If **YES,** we agree because Make the following changes to the AD: If **PARTIALLY AGREE** , we agree with because We disagree with because Make the following changes to the AD:

### Page 2 of 3

If **NO** , we don’t agree because **For additional issues, do uble**  **- click**  **here**

### Page 3 of 3 **S ignature Section**  Signature indicates concurrence with this action. Originating Office Tracking No.: **ASE** Printed Name **: Date** 

**Branch M anager**  **Date**
# C_2014253EN.01003002.xml

| 4.8.2014 | EN | Official Journal of the European Union | C 253/30 |
| --- | --- | --- | --- |

4.8.2014

EN

Official Journal of the European Union

C 253/30

---

Action brought on 14 April 2014 — Chemo Ibérica v OHIM — Novartis (EXELTIS)

(Case T-252/14)

2014/C 253/44

Language in which the application was lodged: Spanish

Parties

Parties

Applicant: Chemo Ibérica, SA (Barcelona, Spain) (represented by: M.I. Escudero Pérez, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other party to the proceedings before the Board of Appeal: Novartis AG (Basel, Switzerland)

Other party to the proceedings before the Board of Appeal:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | annul the decision of the Fourth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 10 February 2014 in Case R 936/2013-4, and accordingly order that Community trade mark No 1 0 2 48  367‘EXELTIS’ should be granted in relation to Class 5 of the International Classification; |
| --- | --- |

—

annul the decision of the Fourth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 10 February 2014 in Case R 936/2013-4, and accordingly order that Community trade mark No 1 0 2 48  367‘EXELTIS’ should be granted in relation to Class 5 of the International Classification;

| — | order the defendant and/or the other party to the proceedings to pay the costs of the proceedings. |
| --- | --- |

—

order the defendant and/or the other party to the proceedings to pay the costs of the proceedings.

Pleas in law and main arguments

Pleas in law and main arguments

Applicant for a Community trade mark: Chemo Ibérica, SA

Applicant for a Community trade mark:

Community trade mark concerned: Word mark ‘EXELTIS’ for goods in Class 5 — Community trade mark application No 1 0 2 48  367

Community trade mark concerned:

Proprietor of the mark or sign cited in the opposition proceedings: Novartis AG

Proprietor of the mark or sign cited in the opposition proceedings:

Mark or sign cited in opposition: Word mark ‘EXELON’ for goods in Class 5

Mark or sign cited in opposition:

Decision of the Opposition Division: Application rejected

Decision of the Opposition Division:

Decision of the Board of Appeal: Appeal dismissed

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 8(1)(b) of Regulation No 207/2009.

Pleas in law:

---
<PAGE>   1

EXHIBIT 15.1

               LETTER RE: UNAUDITED INTERIM FINANCIAL INFORMATION

  We are aware of the incorporation by reference in the Registration Statements
  and related Prospectuses of our report dated January 24, 2000, relating to the
  unaudited consolidated condensed interim financial statements of STERIS
  Corporation and Subsidiaries that are included in its Form 10-Q for the
  quarter ended December 31, 1999:

<TABLE>
<CAPTION>
     Registration
       Number                                           Description                                            Filing Date
-------------------      -----------------------------------------------------------------------      ---------------------------
<S>                      <C>                                                                          <C>
   333-65155               Form S-8 Registration Statement -- STERIS                                    October 1, 1998
                           Corporation Long Term Incentive Stock Plan

   333-55839               Form S-8 Registration Statement -- Nonqualified Stock                        June 2, 1998
                           Option Agreement between STERIS Corporation and
                           John Masefield and the Nonqualified Stock Option
                           Agreement between STERIS Corporation and Thomas
                           J. DeAngelo

   333-32005               Form S-8 Registration Statement -- STERIS                                    July 24, 1997
                           Corporation 1997 Stock Option Plan

   333-06529               Form S-3 Registration Statement -- STERIS                                    June 21, 1996
                           Corporation

   333-01610               Post-effective Amendment to Form S-4 on Form S-8 --                          May 16, 1996
                           STERIS Corporation

   33-91444                Form S-8 Registration Statement -- STERIS                                    April 24, 1995
                           Corporation 1994 Equity Compensation Plan

   33-91442                Form S-8 Registration Statement -- STERIS                                    April 24, 1995
                           Corporation 1994 Nonemployee Directors Equity
                           Compensation Plan

   33-55976                Form S-8 Registration Statement -- STERIS                                    December 21, 1992
                           Corporation 401(k)Plan

   33-55258                Form S-8 Registration Statement -- STERIS                                    December 4, 1992
                           Corporation Amended and Restated Non-Qualified
                           Stock Option Plan
</TABLE>

  Pursuant to Rule 436(c) of the Securities Act of 1933 our reports are not a
  part of the registration statement prepared or certified by accountants within
  the meaning of Section 7 or 11 of the Securities Act of 1933.

                                                           Ernst & Young LLP

   Cleveland, Ohio
   February 11, 2000
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1678 Tacrolimus test system. ( a ) *Identification.* A tacrolimus test system is a device intended to quantitatively determine tacrolimus concentrations as an aid in the management of transplant patients receiving therapy with this drug. This generic type of device includes immunoassays and chromatographic assays for tacrolimus.
( b ) *Classification.* Class II (special controls). The special control is “Class II Special Controls Guidance Document: Cyclosporine and Tacrolimus Assays; Guidance for Industry and FDA.” See § 862.1(d) for the availability of this guidance document.
[67 FR 58329, Sept. 16, 2002]